Top 7 Precision Medicine Companies Tackling Oncological Disorders

Published: December 2023


Research on precision medicine has advanced considerably, owing to the increased preference for personalized diagnosis and treatments and is anticipated to grow substantially in the long-run and the profiled precision medicine companies are in a great position to reap the benefits.
We analyzed over 125 precision medicine companies that are engaged in the development of therapeutics medicines for various oncological disorders. In this article, discover 7 precision medicine companies and their capabilities in this industry


With advancements in genome profiling, precision medicine is rapidly transforming the dimensions of cancer care and management.  Precision medicine in oncology, also referred to as precision oncology, employs genetic testing to determine the genetic characteristics of the patient’s cancerous tumor and customizes the best-suited treatment option. The method correlates the information from the diagnostic test with the medical records of the patient using various emerging technologies, such as next generation sequencing, artificial intelligence, computational biology, machine learning algorithms and digital biomarkers. The incorporation of such technologies aids in the improvement of omics-based studies, enabling the oncologists to refine treatment and prevention strategies for their patients.

The primary aim of precision medicine is to ensure accurate diagnosis and tailored treatment approaches for each individual, delivered at the appropriate time with an accurate dosage.  As a result, the targeted treatment prevents the cancerous cells expressing the identified genetic biomarker from proliferating and developing, thereby, safeguarding the normal cells, while causing minimal side effects.  It is worth mentioning that, considering the various benefits of precision medicine in cancer, regulatory authorities, such as the US FDA is encouraging more research and development initiatives in this domain. In fact, in 2022, more than ten personalized medicines were approved by the US FDA; of these, seven approved drugs are indicated for use in different types of cancer. Additionally, a new personalized therapy has recently been approved for patients suffering from uveal melanoma, a rare eye cancer expressing glycoprotein-100 (Gp-100) cell surface marker.

Roots Analysis has conducted an exhaustive study on Precision Medicine in Oncology Market featuring the current market landscape and future opportunity for the developers involved in precision medicine, over a span of 12 years.

Table of Contents

Below, we have listed (in alphabetical order), the top 7 precision medicine companies. 

  1. AstraZeneca 
  2. Genentech
  3. Jiangsu Hengrui Pharmaceuticals
  4. Johnson & Johnson Innovative Medicine
  5. Novartis
  6. Pfizer
  7. SpringWorks Therapeutics

Top 7 Precision Medicine companies

Interested in exploring all 125+ Precision Medicine Companies and their recent initiatives?

Discover Below the Details on Top 7 Precision Medicine Companies Working in the Oncology Market

Let us deep dive to understand the current status of drugs being developed by top 7 precision medicine companies (shortlisted on the basis of number of drugs in their respective pipeline) in oncology market.

AstraZeneca is Integrating Artificial Intelligence to Streamline and Accelerate Clinical Trials of its Precision Oncology Drug Candidates

1. AstraZeneca

AstraZeneca is a leading biopharmaceutical company involved in the development and commercialization of prescription drugs across three operating segments namely BioPharmaceuticals, Rare Diseases and Oncology. Within Oncology, the company primarily focuses on discovering and developing novel therapeutics for blood cancer, breast cancer, gastrointestinal cancer, gynecological / genitourinary cancer and lung cancer.

AstraZeneca: Company Details

Product Name Type of Bioreactor Detected 
Company Logo AstraZeneca-Precision-Medicine-companies
Location of Headquarters  England, UK
Year of Establishment 1999
Number of Employees 10,000+

The following table presents the details of one of the precision medicine for oncology developed by AstraZeneca.

AstraZeneca: Precision Medicine in Oncology Drug Portfolio

Drug Specificaitons 
Anastrozole  
  • Brand Name: ARIMIDEX®
  • Type of Molecule: Small Molecule
  • Drug Class: Antineoplastics Aromatase Inhibitor
  • Target Gene / Protein: HR
  • Current Stage of Development: Commercialized 
  • Approval Body: FDA, Health Canada, TGA
  • Approval Region: North America, Asia-Pacific
  • Drug Designations: Accelerated Approval, Fast Track, Priority Review
  • Route of Administration: Oral
  • Dosing Frequency: Once Daily
  • Age: ≥ 18 years
  • Target Indication: Breast Cancer

In addition to the above drug, the AstraZeneca is developing multiple personalized medicine in oncology candidates, on which details are available in the full report.

Partnership Signed by AstraZeneca Focusing on Precision Medicine in Oncology: In January 2022, AstraZeneca entered into a strategic partnership with Scorpion Therapeutics to discover, develop and commercialize precision medicine for hard-to-treat cancer.

Further details on recent initiatives taken by AstraZeneca and other precision medicine companies have been provided in detail in the report.
 

Genentech is Incorporating Big Data Analytics to Identify Genomic Patterns in Cancer Patients for the Future Development of Target-specific Medicine

2. Genentech

Genentech is a leading biotechnology firm which specializes in the delivery of innovative therapeutic entities for patients with life threatening medical disorders. With an experience of more than 45 years, the company has developed a broad portfolio of drugs in various therapeutic areas such as infectious diseases, immunology, neuroscience, ophthalmology and oncological disorders. Additionally, the company is leveraging advanced technologies such as genome sequencing to discover and develop precision medicines for various target indications across the domain of oncology.

Genentech: Company Details

Product Name Type of Bioreactor Detected 
Company Logo Genentech-Precision-Medicine-companies
Location of Headquarters  California, US
Year of Establishment 1976
Number of Employees 10,000+

The following table presents the details of one of the precision medicine for oncology developed by Genentech.

Genentech: Precision Medicine in Oncology Drug Portfolio

Drug Specificaitons 
Ado-trastuzumab emtansine  
  • Brand Name: Kadcyla
  • Type of Molecule: Biologics (Monoclonal Antibody)
  • Drug Class: HER2 Inhibitor
  • Target Gene / Protein: HER2
  • Current Stage of Development: Commercialized 
  • Approval Body: FDA, European Commission, EMA, Health Canada, MHLW
  • Approval Region: North America, Europe, Asia-Pacific
  • Drug Designations: Accelerated Approval, Breakthrough therapy, Priority Review
  • Route of Administration: Intravenous
  • Dosing Frequency: Every Three Weeks
  • Age: ≥ 18 years
  • Target Indication: Breast Cancer

In addition to the above drug, the Genentech developed / developing multiple personalized medicine in oncology, on which details are available in full report.

Partnership Signed by Genentech focusing on Precision Medicine in Oncology: Genentech has collaborated with diagnostic companies such as Foundation Medicine and Flatiron Health to enhance next-generation sequencing tests and data analytics. This will aid the company to improve and accelerate the clinical evaluation of the novel precision drugs. 

Further details on recent initiatives taken by Genentech and other precision medicine companies have been provided in detail in the report.
 

Precision Medicine Drugs Being Developed by Jiangsu Hengrui Pharmaceuticals have Reached Late-stage Clinical Trials

3. Jiangsu Hengrui Pharmaceuticals

Jiangsu Hengrui Pharmaceuticals is a global pharmaceutical organization renowned for its expertise in the development and distribution of high-quality therapeutic drugs.  The company offers a robust research and development pipeline on therapeutic areas such as autoimmune diseases, cardiovascular diseases, infectious diseases, oncology and pain management.

Jiangsu Hengrui Pharmaceuticals: Company Details

Product Name Type of Bioreactor Detected 
Company Logo Jiangsu-Hengrui-Pharmaceuticals-Precision-Medicine-companies
Location of Headquarters   Lianyungang, China
Year of Establishment 1970
Number of Employees 10,000+

The following table presents the details of one of the precision medicine for oncology developed by Jiangsu Hengrui Pharmaceuticals.

Jiangsu Hengrui Pharmaceuticals: Precision Medicine in Oncology Drug Portfolio

Drug Specificaitons 
Apatinib / Rivoceranib  
  • Brand Name: Aitan
  • Type of Molecule: Small Molecule
  • Drug Class: VEGF / VEGFR Inhibitor
  • Target Gene / Protein: VEGFR-2
  • Current Stage of Development: Commercialized 
  • Approval Body: NMPA
  • Approval Region: Asia-Pacific
  • Drug Designations: Orphan Drug
  • Route of Administration: Oral
  • Dosing Frequency: Once Daily / Twice Daily
  • Age: ≥ 18 years
  • Target Indication: Gastrointestinal Cancer

In addition to the above drug, the Jiangsu Hengrui Pharmaceuticals developed / developing multiple personalized medicine in oncology, on which details are available in full report.

Partnership Signed by Jiangsu Hengrui Pharmaceuticals focusing on Precision Medicine in Oncology: In October 2018, Jiangsu Hengrui Pharmaceuticals established a partnership with Elevar Therapeutics to clinically study the effectiveness of Aitan, a precision oncology drug, in patients with advanced hepatocellular carcinoma. More recently, a commercialization agreement has been announced.2

Further details on recent initiatives taken by Jiangsu Hengrui Pharmaceuticals and other precision medicine companies have been provided in detail in the report.
 

Johnson and Johnson Innovative Medicine has Successfully Commercialized Eight Precision Medicines for Different Oncological Disorders

4. Johnson & Johnson Innovative Medicine (earlier known as Janssen Pharmaceuticals)

Johnson & Johnson Innovative Medicine is a leading pharmaceutical research and manufacturing company specialized in the development of innovative therapeutic solutions for various medical disorders. The firm operates through three distinct segments namely Consumer Health, Pharmaceutical and MedTech.  Within the Pharmaceutical division, the company offers a diverse pipeline of drugs with a primary focus on the areas such as cardiovascular, immunology, infectious diseases, neuroscience, oncology, and pulmonary hypertension.  It is worth highlighting that in the recent years the firm has made significant investments in research and development of precision medicines for oncology domain.

The following table presents the details of one of the precision medicine for oncology developed by Johnson & Johnson Innovative Medicine.

Johnson & Johnson Innovative Medicine: Company Details

Product Name Type of Bioreactor Detected 
Company Logo Johnson-&-Johnson-Innovative-Medicine-Precision-Medicine-companies
Location of Headquarters   New Jersey, US
Year of Establishment 1953
Number of Employees 10,000+

Johnson & Johnson Innovative Medicine: Precision Medicine in Oncology Drug Portfolio

Drug Specificaitons 
Abiraterone Acetate  
  • Brand Name: ZYTIGA
  • Type of Molecule: Small Molecule
  • Drug Class: Antiandrogen
  • Target Gene / Protein: CYP17
  • Current Stage of Development: Commercialized 
  • Approval Body: FDA, European Commission, EMA, Health Canada, PMDA
  • Approval Region: North America, Europe, Asia-Pacific
  • Drug Designations: Priority Review
  • Route of Administration: Oral
  • Dosing Frequency: Once Daily
  • Age: ≥ 18 years
  • Target Indication: Reproductive Cancer

In addition to the above drug, the Johnson & Johnson Innovative Medicine developed / developing multiple personalized medicine in oncology, on which details are available in full report.

Further details on recent initiatives taken by Johnson & Johnson Innovative Medicine and other precision medicine companies have been provided in detail in the report.
 

Novartis is One of the Precision Medicine Companies Innovating New Practices Discover Novel Drug Targets to Strengthen its Precision Oncology Portfolio

5. Novartis

Novartis is one of the largest multinational healthcare companies in the world contributing to the discovery and development of breakthrough therapies to address some of the most challenging health conditions. The firm leverages innovative technologies, and research and development strategies to produce high-value medicines that have consistently improved the patient’s quality of life over the past two decades. With a comprehensive understanding of cancer biology, the firm is advancing its approach to build a robust pipeline of precision medicine in oncology.

Novartis: Company Details

Product Name Type of Bioreactor Detected 
Company Logo Novartis-Precision-Medicine-companies
Location of Headquarters   Basel, Switzerland
Year of Establishment 1996
Number of Employees 10,000+

The following table presents the details of one of the precision medicine for oncology developed by Novartis.

Novartis: Precision Medicine in Oncology Drug Portfolio

Drug Specificaitons 
Alpelisib  
  • Brand Name: Piqray
  • Type of Molecule: Small Molecule
  • Drug Class: PI3K Inhibitor
  • Target Gene / Protein: PIK3CA
  • Current Stage of Development: Commercialized 
  • Approval Body: FDA, European Commission, TGA
  • Approval Region: North America, Europe
  • Drug Designations: Priority Review
  • Route of Administration: Oral
  • Dosing Frequency: Once Daily
  • Age: ≥ 18 years
  • Target Indication: Bladder Cancer

In addition to the above drug, the Novartis developed / developing multiple personalized medicine in oncology, on which details are available in full report.

Further details on recent initiatives taken by Novartis and other precision medicine companies have been provided in detail in the report.
 

Pfizer has Successfully Developed and Commercialized Over 15 Precision Medicine Drugs for the Treatment of Different Oncology Target Indications

6. Pfizer

Pfizer is a leading biopharmaceutical company engaged in the research and development of revolutionary therapeutics to improve and transform the life of patients suffering from various medical conditions.  The company offers a robust pipeline of drugs and vaccines for a wide range of therapeutic areas such as oncological disorders, infectious and rare diseases.  Within the oncology segment, the company primarily focuses on precision medicine, tumor targeted therapeutics, tumor cell biology, integrative biotechnology and immune oncology.

Pfizer: Company Details

Product Name Type of Bioreactor Detected 
Company Logo Pfizer-Precision-Medicine-companies
Location of Headquarters   New York, US
Year of Establishment 1849
Number of Employees 10,000+

The following table presents the details of one of the precision medicine for oncology developed by Pfizer.

Pfizer: Precision Medicine in Oncology Drug Portfolio

Drug Specificaitons 
Avelumab  
  • Brand Name: BAVENCIO
  • Type of Molecule: Biologics (Monoclonal Antibody)
  • Drug Class: PD-1 PD-L1 Inhibitor
  • Target Gene / Protein: PD-L1
  • Current Stage of Development: Commercialized 
  • Approval Body: FDA, European Commission, EMA, Health Canada, MHLW, TGA
  • Approval Region: North America, Europe, Asia-Pacific
  • Drug Designations: Accelerated Approval, Breakthrough therapy, Fast Track, Orphan Drug, Priority Review
  • Route of Administration: Intravenous
  • Dosing Frequency: Every Two Weeks
  • Age: ≥ 12 years
  • Target Indication: Bladder Cancer, Skin Cancer / Melanoma

In addition to the above drug, the Pfizer developed / developing multiple personalized medicine in oncology, on which details are available in full report.

Partnership Signed by Pfizer Focusing on Precision Medicine in Oncology: In May 2023, Pfizer entered into a strategic partnership with Thermo Fisher Scientific to augment the access to next generation sequencing-based tests for breast and lung cancer across Latin America and MENA.3 Moreover, in March 2023, Pfizer announced the acquisition of Seagen to advance its existing oncology portfolio across breast cancer, genitourinary cancer, hematology and precision medicine.4 

Further details on recent initiatives taken by Pfizer and other precision medicine companies have been provided in detail in the report.
 

SpringWorks Therapeutics has Successfully Advanced its Two Lead Drug Candidates (Mirdametinib and Nirogacestat) to the Later Stages of Clinical Trials

7. SpringWorks Therapeutics

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company which focuses on the development of life-changing medicine for rare diseases and oncological disorders. With the application of precision medicine approach, the firm has developed a distinct pipeline of small molecule drugs for various oncology indications ranging from solid tumors to hematologic cancers.

SpringWorks Therapeutics: Company Details

Product Name Type of Bioreactor Detected 
Company Logo SpringWorks-Therapeutics-Precision-Medicine-companies
Location of Headquarters   Connecticut, US
Year of Establishment 2017
Number of Employees 51-200

The following table presents the details of one of the precision medicine for oncology developed by SpringWorks Therapeutics.

SpringWorks Therapeutics: Precision Medicine in Oncology Drug Portfolio

Drug Specificaitons 
Brimarafenib / BGB-3245  
  • Type of Molecule: Small Molecule
  • Drug Class: BRAF Inhibitor
  • Target Gene / Protein: BRAF
  • Current Stage of Development: Phase I 
  • Route of Administration: Oral 
  • Dosing Frequency: Once Daily
  • Age: ≥ 18 years
  • Target Indication: Unspecified Solid Tumors

In addition to the above drug, SpringWorks Therapeutics developed / developing multiple personalized medicine in oncology, on which details are available in full report.

Partnership Signed by SpringWorks Therapeutics Focusing on Precision Medicine in Oncology: In April 2022, SpringWorks Therapeutics entered into a strategic partnership with Regeneron Pharmaceuticals to clinically evaluate Nirogacestat in patients with multiple myeloma.

Further details on recent initiatives taken by SpringWorks Therapeutics and other precision medicine companies have been provided in detail in the report.

What about the other Precision Medicine Companies around the world?

The above presentation features seven precision medicine companies for oncology selected from a pool of over 125 players that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

About Author

Nancy_Kapila

I am Nancy Kapila, an accomplished pharmaceutical consultant with a rich and diverse experience spanning more than 5 years. My educational background includes a Master's degree in Pharmaceutics (M.Pharm) from Panjab University, which has provided me with a solid foundation in understanding the intricate mechanisms of drugs and their interactions within the human body. Throughout my professional journey, I have had the privilege of working with various pharmaceutical companies, leveraging my expertise to provide valuable insights and strategic guidance.

What sets me apart is my unwavering commitment to staying at the forefront of the ever-evolving pharmaceutical landscape. In an industry characterized by rapid advancements and dynamic changes, I make it a priority to remain well-informed about the latest developments, regulatory updates, and emerging trends. This continuous learning not only keeps me well-equipped to navigate the complexities of the field but also enables me to offer innovative solutions that drive client success. I am deeply fascinated by the potential of data analytics and its transformative impact on decision-making. By delving into data, I can identify patterns, trends, and opportunities that might otherwise remain hidden. This enables me to provide clients with evidence-based recommendations that optimize processes, enhance product development, and drive operational efficiency.

My journey has been marked by a continuous quest for knowledge, an unrelenting passion for data-driven insights, and an unwavering commitment to guiding pharmaceutical companies towards success in an ever-changing world.

Nancy.Kapila@rootsanalysis.com
https://www.linkedin.com/in/nancy-kapila-4336b4129/

Source1: https://www.astrazeneca.com/media-centre/press-releases/2022/astrazeneca-and-scorpion-therapeutics-enter-agreement-to-discover-develop-and-commercialise-novel-cancer-treatments-against-undruggable-targets.html
Source2: https://elevartherapeutics.com/2023/10/17/elevar-therapeutics-and-jiangsu-hengrui-pharma-announce-global-commercialization-licensing-agreement-for-pd-1-inhibitor-camrelizumab-in-combination-with-rivoceranib-for-uhcc/
Source3: https://www.pfizer.com/news/press-release/press-release-detail/thermo-fisher-scientific-pfizer-partner-expand-localized
Source4: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invests-43-billion-battle-cancer
Source5: https://ir.springworkstx.com/news-releases/news-release-details/springworks-therapeutics-announces-clinical-trial-collaboration

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry